FDA Warning Letter Deadline for Five Peptide Vendors Expires September 8
Five online peptide vendors face a September 8 deadline to respond to FDA warning letters citing unapproved drug sales including semaglutide and tirzepatide.
Category Regulation
FDA Warning Letters Target Five Online Peptide Vendors
FDA issued warning letters to five online peptide sellers for unapproved GLP-1 drugs, with responses due within 15 working days of receipt.
Commentary Warns FDA Fails to Stop Online Peptide Sales
A FinancialContent opinion piece argues online sellers continue marketing unapproved retatrutide despite FDA warning letters, citing an enforcement gap.
PSM Tracks 50 State Board Actions, 160 FDA Letters on GLP-1 Compounders
The Partnership for Safe Medicines has documented 50 state pharmacy board actions and 160 FDA letters targeting unsafe GLP-1 and peptide compounders since 2025.
FDA Warns Five Online Peptide Vendors Over Unapproved GLP-1 Drugs
The FDA issued warning letters to five online peptide vendors, citing the alleged sale of unapproved GLP-1 drugs and research peptides directly to consumers.
Qatar MOPH Bans Handling of Unlicensed Peptide Products
Qatar's MOPH issued Circular PDC/2026/31 prohibiting handling, distribution, use, and promotion of unlicensed peptide products, effective immediately.
Federal Appeals Court Upholds FDA GLP-1 Shortage-End Rulings
A federal appeals court ruled the FDA followed proper process in ending GLP-1 shortage declarations, dealing a loss to compounders challenging the agency.
Sheppard Mullin: PCAC Peptide Votes Advisory Only, Rulemaking Likely to 2027–2028
A new legal analysis confirms FDA's advisory committee votes on six peptides for the 503A Bulks List are nonbinding, with formal rulemaking likely extending into 2027 or 2028.
Eli Lilly Sues Six Companies Over Alleged Illegal Retatrutide Sales
Eli Lilly filed six lawsuits targeting peptide suppliers, a med spa, and a compounding pharmacy for allegedly selling unapproved versions of its experimental obesity drug retatrutide.
PCAC Peptide Votes Are Nonbinding: Mondaq Warns Pharmacies Against Premature Compounding
A Mondaq legal analysis clarifies that July 2026 PCAC votes on six peptides do not authorize compounding. Formal FDA rulemaking is still required.
